Literature DB >> 18926089

Ovarian cancer. Clinical practice guidelines in oncology.

Robert J Morgan1, Ronald D Alvarez, Deborah K Armstrong, Barry Boston, Lee-may Chen, Larry Copeland, Jeff Fowler, David K Gaffney, David Gershenson, Benjamin E Greer, Perry W Grigsby, Laura J Havrilesky, Carolyn Johnston, Johnathan M Lancaster, Shashikant Lele, Ursula Matulonis, David O'Malley, Robert F Ozols, Steven W Remmenga, Paul Sabbatini, Julian Schink, Nelson Teng.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18926089     DOI： 10.6004/jnccn.2008.0058

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


× No keyword cloud information.
  12 in total

1.  Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance.

Authors:  Katia Meirelles; Leo Andrew Benedict; David Dombkowski; David Pepin; Frederic I Preffer; Jose Teixeira; Pradeep Singh Tanwar; Robert H Young; David T MacLaughlin; Patricia K Donahoe; Xiaolong Wei
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-27       Impact factor: 11.205

2.  Distinct subpopulations of epithelial ovarian cancer cells can differentially induce macrophages and T regulatory cells toward a pro-tumor phenotype.

Authors:  Ayesha B Alvero; Michele K Montagna; Vinicius Craveiro; Lanzhen Liu; Gil Mor
Journal:  Am J Reprod Immunol       Date:  2011-09-14       Impact factor: 3.886

3.  Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas.

Authors:  Alison M Karst; Keren Levanon; Sekhar Duraisamy; Joyce F Liu; Michelle S Hirsch; Jonathan L Hecht; Ronny Drapkin
Journal:  Gynecol Oncol       Date:  2011-06-17       Impact factor: 5.482

4.  Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies.

Authors:  Gerald S Falchook; Siqing Fu; Aung Naing; David S Hong; Wei Hu; Stacy Moulder; Jennifer J Wheler; Anil K Sood; Ernesto Bustinza-Linares; Kristin L Parkhurst; Razelle Kurzrock
Journal:  Invest New Drugs       Date:  2013-08-02       Impact factor: 3.850

5.  Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.

Authors:  Siqing Fu; Wei Hu; Revathy Iyer; John J Kavanagh; Robert L Coleman; Charles F Levenback; Anil K Sood; Judith K Wolf; David M Gershenson; Maurie Markman; Bryan T Hennessy; Razelle Kurzrock; Robert C Bast
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

6.  Risk factors and indications for 30-day readmission after primary surgery for epithelial ovarian cancer.

Authors:  Mariam AlHilli; Carrie Langstraat; Christine Tran; Janice Martin; Amy Weaver; Michaela McGree; Andrea Mariani; William Cliby; Jamie Bakkum-Gamez
Journal:  Int J Gynecol Cancer       Date:  2015-02       Impact factor: 3.437

7.  The use of CT findings to predict extent of tumor at primary surgery for ovarian cancer.

Authors:  Gretchen Glaser; Michelle Torres; Bohyun Kim; Giovanni Aletti; Amy Weaver; Andrea Mariani; Lynn Hartmann; William Cliby
Journal:  Gynecol Oncol       Date:  2013-05-11       Impact factor: 5.482

Review 8.  Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer.

Authors:  Natalie J Carter; Susan J Keam
Journal:  Drugs       Date:  2010-02-12       Impact factor: 9.546

9.  Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study group.

Authors:  A du Bois; I Vergote; P Wimberger; I Ray-Coquard; P Harter; L B Curtis; I Mitrica
Journal:  Br J Cancer       Date:  2012-01-12       Impact factor: 7.640

Review 10.  Tumor-associated macrophages contribute to tumor progression in ovarian cancer.

Authors:  Emily K Colvin
Journal:  Front Oncol       Date:  2014-06-06       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.